Pfizer’s Quest For COVID Vaccine Correlates Of Protection Running Into Roadblocks
Executive Summary
Pfizer scientists said they are having trouble identifying an immune correlate of protection for the company's COVID-19 vaccine, while other scientists expressed optimism that neutralizing antibodies might eventually be able to be used as a correlate, though there were some questions raised about using them for booster decision making.
You may also be interested in...
COVID Vaccines: US FDA Should Play More Activist Role In Development Of Modified Formulations
Advisory committee tells FDA that the agency, not vaccine manufacturers, should dictate the conversation around variants and reformulations; panelists also want better government research on immune correlates of protection ahead of any decision on a composition change.
Mix and Match COVID Boosters: Time Crunch For Data Review May Mean No Advisory Committee Vote
US FDA can’t say whether it will have its vaccine advisors vote on the heterologous uses of booster doses at its 14-15 October meeting of the Vaccines and Related Biological Products Advisory Committee because it is still reviewing the data. The Agency does not appear to need a formal company application or emergency use authorization amendment to allow this type of boosting.
From ‘Booster-For-All’ To ‘Pfizer-For-Some’: Lessons From The Third Shot Debate
Biden Administration met its self-declared goal of launching a booster campaign ‘the week of September 20’ – but with a more complex messaging challenge than anyone could have wanted after US FDA authorization and CDC recommendation for a ‘booster’ dose of Pfizer/BioNTech’s COVID vaccine left considerable confusion about who should get a third shot.